Benefits and Risks of ART
|
|
- Cory Manning
- 5 years ago
- Views:
Transcription
1 Benefits and Risks of ART Dr Paula Munderi WHO Training Course for Introducing Pharmacovigilance of HIV Medicines November 2009, Dar Es Salaam
2 Summary Progress in ART coverage WHO Progress Report Benefits of ART Survival Decreased Morbidity Decreased Transmission Vertical & Horizontal Principles of ART Measurement of efficacy Risks of ART linked to AEs and Toxicities Special Populations : Women & Children Epidemiology of Paediatric HIV Pregnancy and ART Co morbidities of specific concern : TB, HepB, Hep C, (Malaria) Programme implications Selection of ARVs in the PH approach ART principles & recommendations Current ART practice in LMIC What this means for countries Adherence : determinant of ART efficacy
3 Acknowledgements Sources of Slide Material Published data WHO progress report on access 2009 Jens Lundgren Lynne Moffenson WHO HQ HIV Dept (ATC team) DART study group
4 I Benefits of ART Improved Survival Reduced morbidity Reduced vertical transmission of HIV Possibly reduced horizontal transmission of HIV
5 Number of people receiving antiretroviral therapy in low and middle income countries, by region, Millions North Africa and the Middle East Europe and Central Asia East, South and South-East Asia Latin America and the Caribbean Sub-Saharan Africa End 2002 End 2003 End 2004 End 2005 End 2006 End 2007 End 2008
6 Reduced Death rates over time on ART Rate per 100 person years 0 1 years 17.9 [ ] 1 2 years 2.3 [ ] 2 3 years 1.2 [ ] Castelnuovo B, Manabe YC, Kiragga A et al CID 2009; 49:965 72
7 Survival impact of ART Proportion alive DART cohort ART: LCM: 2.2/100 PY CDM: 2.9/100 PY median CD4 86 at enrolment Entebbe Cohort (same community) NO ART available Years from enrolment into cohort median CD4 75 at enrolment 57.7/100 PY DART Study Group. IAS July 2009
8 Impact of ART on causes of death DART Study Group: XVI INTERNATIONAL AIDS CONFERENCE 2006 Pre-ART cohort: EC n = 516 PYO = 658 Oct 95 - Dec 00 Deaths (rate/100py) Post-ART cohort: DART n = 1015 PYO = 1819 Feb 03 - Jan 06 Deaths (rate/100py) Specific HIV-related causes 118 (17.9) 27 (1.5) Cryptococcus 64 (9.7) 4 (0.2) Cryptosporidium 18 (2.7) 2 (0.1) Tuberculosis 16 (2.4) 10 (0.5) HIV-related malignancy 11 (1.7) 6 (0.3) Bacteraemia 3 (0.5) 5 (0.3) CMV 4 (0.6) 0 (0) Severe anaemia 2 (0.3) 0 (0) Syndrome likely HIV related 176 (26.7) 18 (1.0) Wasting (+/- diarrhoea) 111 (16.9) 1 (0.1) Febrile event 48 (7.3) 12 (0.7) Neurological event 17 (2.6) 5 (0.3) Cause not HIV-related 4 (0.6) 6 (0.3) Unknown cause 82 (12.6) 11 (0.6) Total deaths 380 (57.7) 62 (0.3)
9 Malaria DART cohort
10 Vertical Transmission Maternal Viral Load in absence of ART % Transmission % 6% < % % % > Delivery Plasma HIV RNA Blattner W. XIII AIDS Conf, July 2000, Durban S Africa (LBOr4) WITS study,
11 Timing of vertical transmission for 30% 15 % 5% 10% Pregnancy Pre-natal DE LIV ER Y Breast-feeding Post-natal
12 Vertical Transmission at 6 weeks postpartum by ARV Regimen Botswana National Data Oct 2006 Nov 2007 Tlale J et al. IAS Mexico City Aug 2008 (Abs ThAC04) 15% Most Women Formula Feed Their Infants 10% 12.3% 5% 7.0% 4.7% 0% 0.7% 2.3% cart pre-preg cart during preg 3.3% AZT >4 wk +sdnvp AZT <4 wk +sdnvp sdnvp No ART
13 Vertical transmission of HIV 15-35% <1% Antenatal screen Maternal ART Neonatal ART C. section No breastfeeding
14 «Les personnes séropositives ne souffrant d aucune autre MST et suivant un traitement antirétroviral efficace ne transmettent pas le VIH par voie sexuelle» Commission fédérale pour les problèmes liés au sida (CFS), Commission d experts clinique et thérapie VIH et sida de l Office fédéral de la santé publique (OFSP) P Vernazza, B Hirschel, E Bernasconi, M Flepp. Bulletin des médecins suisses 2008;89: 5 Scientific basis: Effective ART undetectable HIV RNA Epidemiologic basis : vertical transmission is related to plasma HIV RNA e.g PMTCT
15 Longitudinal studies in HIV sero discordant couples Rwanda & Zambia 393 couples followed for 14 years no transmission from person on cart 8.6 % transmission with no cart 1 93 couples; in 41 +ve partner on cart 6 infections all in non treated 2 62 couples; Males +ve pregnancy desired no infection in female partner 3 2, 993 couples followed from HIV testing every 3 months person years 4 HIV infections from partners on cart 171 infections partners not on cart Incidence density of HIV transmission 4 0.7% on cart vs 3.4% off cart [RR = 0.21, CI: 0.08, 0.59] NB: HIV persists in semen and cervicovaginal fluid during effective cart
16 ARVs for Prevention PEP & PMTCT Universal Test & Treat combination ART Pre Exposure prophylaxis (PrEP) Tenofovir ARVs as vaginal microbicides Tenofovir Maraviroc
17 II Principles of ART Combination therapy Avoidance of resistance Importance of adherence
18 For sustained efficacy of ART... synergistic combinations of 3 active drugs usually from 2 different classes single or dual drug therapy only in PMTCT; low risk PEP the large number of possible combinations is only apparent cross resistance develops within classes Cross resistance may occur between NRTIs and NNRTIs preserving future treatment options is critical choice of initial regimen rational sequencing of combinations thereafter
19 Measurement of efficacy of ART When is treatment working? When has treatment failed Absence of clinical disease WHO clinical staging Recurrence of clinical illness WHO stage II/III/IV Immune restoration Rise in CD4 count Viral suppression Undetectable VL Fall in CD4 count to below 100 cells/mm 3 Detectable VL to >5000 copies/ml
20 Resistant virus Wild-type virus 10-20%
21 Resistant virus Wild-type virus Drug pressure 10-20%
22 Adherence Efficacy Nachega et al, Ann Intern Med, 2007
23 III Risks of ART Mainly related to toxicities
24 NB: Most ART Toxicities are... Predictable Clinically detectable Can be managed The key is patient and provider education!
25 Italian Cohort I C O N A Naive Antiretroviral Main reasons of discontinuation of first cart regimen within 1st year: ICONA cohort Toxicity Failure Non-adherence Other Continued Monforte et al. AIDS 1999
26 Reasons for change of a first combination ART regimen Reason N CD4 VL Unknown Other Choice Toxicities Failure p=0.27 p< N Median CD p= Median VL p= EuroSIDA: Mocroft et al, AIDS Research Hum Retro, 2005
27 ART Toxicity related deaths: 1 st year 1 Hepatotoxicity, 2 Lactic acidosis 2 nd year 1 Hepatotoxicity; 2 lactic acidosis; 1 pancreatitis Castelnuovo B, Manabe YC, Kiragga A et al CID 2009; 49:965 72
28 NB: Most ART Toxicities are... Predictable Clinically detectable Can be managed The key is patient and provider education!
29 IV Women & Children Pregnancy In utero & Perinatal exposure to ARVs cart in children
30 Incidence of Seroconversion in Pregnancy: Prevention of HIV in Pregnant Women is Critical Country Reference Incidence per 100 Pt Yrs Pregnancy Uganda Gray R et al. Lancet 2005;366: Botswana Lu L et al CROI Abs.94LB 1.3 ( ) Zimbabwe, Uganda South Africa Morrison CS et al. AIDS 2007;21:1027 Rehle T et al. S Afr Med J 2007;97: (0 12.9) South Africa Moodley D et al. AIDS 2009;23: ( )
31 43% of New Infant Infections in Botswana May be Due to Maternal Seroconversion in Pregnancy/PP Lu L et al. 16 th CROI, Montreal, Canada Feb 2009 Abs 94LB HIV diagnosed before or during ANC New maternal infection late pregnancy New maternal infection 1 yr postpartum # HIV+ women Estimated MTCT rate # infected infants 13, (incidence 1.3%) 4.7% (with PMTCT ARV) 450 (incidence 1.8%) 73% 36% Of the estimated 1,082 infant HIV infections in Botswana in 2007, 462 (43%) were due to incident cases of maternal HIV in pregnancy/pp
32 Prevention of HIV in Women, (Especially Young Women) Prevention of Unintended Pregnancies in HIV-Infected Women Prevention of Transmissio n from an HIV-Infected Woman to Her Infant Support for HIV-Infected Mother and Family Unintended Pregnancy Among HIV Infected Women 51% unintended pregnancies among women with HIV in Cote d Ivoire. 74% unintended pregnancies among women in HIV care in Rwanda. 84% unintended pregnancies among PMTCT clients in South Africa. 93% unintended pregnancies among women in HIV-ART care in Uganda. Desgrees du Lou Aet al. Int J STD AIDS 2002 Bangendanye, 3 rd Ped CLS 2007 Rochet T et al. JAMA 2006 Homsy J et al. PLosOne 2009
33 Incident pregnancy on ART DART cohort Age at enrolment yrs yrs yrs yrs All women <45 Incidence rate per 100 woman years <1 year 1 2 years 2 3 years 3 4 years >4 years Time since enrolment in DART
34 Increased plasma volume dilution effect Physiologic Changes During Pregnancy Can Affect Therapeutic Drug Administration Decreased in serum albumin increase in free fraction of drug Increased GFR 20 60% starting 1 st trimester change in drug clearance Changes in hepatic enzyme activity increase CYP34A, 2D6 = change in drug metabolism Decreased gastric acid secretion, prolonged gastric emptying and intestinal transit time decreased oral drug absorption
35 Pregnancy & Antiretroviral Pharmacokinetics NRTIs Abacavir Didanosine Emtricitabine Lamivudine Stavudine Zidovudine NUCLEOTIDES Tenofovir AUC No No No No No No NNRTIs Efavirenz No data Etravirine No data Nevirapine No FUSION INHIBITORS Enfuvirtide No data PIs Atazanavir AUC Darunavir No data Fosamprenavir AUC? Indinavir AUC Lopinavir/rit AUC Nelfinavir AUC Ritonavir AUC Saquinavir AUC Tipranavir No data CCR5 CO-RECEPTOR ANTAGONISTS Maraviroc No data INTEGRASE INHIBITORS Raltegravir No data
36 Toxicity associations in pregnancy Maternal Foetal d4t / ddi lactic acidosis NEVIRAPINE hepatic toxicity EFAVIRENZ neural tube defects TENOFOVIR bone growth defects ZIDOVUDINE anaemia
37 Antiretroviral Pregnancy Registry 1/89 1/09 Prospective Cases ( % Birth Defect CDC general birth defect surveillance 2.7% ( %) 1 st trimester any ARV exposure 2.9% ( %) Atazanavir sulfate-containing (7/292) ABC-containing (18/608) AZT-containing (95/3108) 3TC-containing (93/3226) d4t-containing (19/754) Indinavir-containing (6/276) Nelfinavir-containing (37/1074) Nevirapine-containing (18/817) Ritonavir-containing (20/883) Lopinavir-containing (8/470) Tenofovir-containing (16/678) ddi-containing (16/365) 2.4% ( %) 3.0% ( %) 3.1% ( %) 2.9% ( %) 2.5% ( %) 2.2% ( %) 3.4% ( %) 2.2% ( %) 2.3% ( %) 1.7% ( %) 2.4% ( %) 4.4% ( %)
38 HIV negative but exposed children following in utero exposure to ARVs Clinically symptomatic mitochondrial dysfunction rare 0.3% 3 per 1,000 very rarely (0.07% 7 per 10,000) can be fatal Mild, clinically asymptomatic, but persistent hematologic abnormalities anaemia, neutropenia Transient elevations in lactic acid common with in utero exposure usually asymptomatic resolve within months
39
40 ARV toxicities in treated children similar spectrum to adults Of particular importance in children: Metabolic abnormalities hyperlipidaemia glucose intolerance Fat redistribution Bone density & growth
The use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines
The use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines I. Boucoiran, T. Lee, K. Tulloch, L. Sauve, L. Samson, J. Brophy, M. Boucher and D. Money For and
More informationPharmacological considerations on the use of ARVs in pregnancy
Pharmacological considerations on the use of ARVs in pregnancy 11 th Residential Course on Clinical Pharmacology of Antiretrovirals Torino, 20-22 January 2016 Prof. David Burger, PharmD, PhD david.burger@radboudumc.nl
More informationART and Prevention: What do we know?
ART and Prevention: What do we know? Biomedical Issues Trip Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Cornell Medical College New York City ART for Prevention:
More informationAntiretroviral Therapy During Pregnancy and Delivery: 2015 Update
Frontier AIDS Education and Training Center Antiretroviral Therapy During Pregnancy and Delivery: 2015 Update Brian R. Wood, MD Assistant Professor of Medicine, University of Washington Medical Director,
More informationUpdate on Antiretroviral Treatment for HIV Infection 2008
Update on Antiretroviral Treatment for HIV Infection 2008 Janet Gilmour MD FRCP(C) Clinical Associate Professor of Medicine University of Calgary November 2008 Disclosure and Acknowledgements Disclosure:
More informationHIV basics. Katya Calvo Medical Director of Antimicrobial Stewardship
HIV basics Katya Calvo Medical Director of Antimicrobial Stewardship Learning Objectives 1. Review of HIV epidemiology worldwide and locally 2. Review of recommendations on whom to screen 3. Work up of
More informationMother to Child HIV Transmission
Koff WC. NEJM 2010;363:e7 Mother to Child HIV Transmission Why We Still Need New Prevention Modalities Lynne M. Mofenson, M.D. Maternal and Pediatric Infectious Disease Branch Eunice Kennedy Shriver National
More informationTB Intensive Tyler, Texas December 2-4, Tuberculosis and HIV Co-Infection. Lisa Y. Armitige, MD, PhD. December 4, 2008.
TB Intensive Tyler, Texas December 2-4, 2008 Tuberculosis and HIV Co-Infection Lisa Y. Armitige, MD, Ph.D. December 4, 2008 Tuberculosis and HIV Co Infection Lisa Y. Armitige, MD, PhD Assistant Professor
More informationPediatric HIV Infection and the Medical Management of Pregnant Women infected with HIV. Ernesto Parra, M.D., M.P.H.
Pediatric HIV Infection and the Medical Management of Pregnant Women infected with HIV Ernesto Parra, M.D., M.P.H. Adjunct Associate Professor UTHSCSA Department of Pediatrics and Family and Community
More informationElimination of mother to child transmission of HIV: is the end really in sight? Lisa L. Abuogi, MD University of Colorado, Denver Dec 3, 2014
Elimination of mother to child transmission of HIV: is the end really in sight? Lisa L. Abuogi, MD University of Colorado, Denver Dec 3, 2014 Outline Background History of prevention of mother to child
More informationTB/HIV Co-Infection. Tuberculosis and HIV
TB Intensive Tyler, Texas June 2-4, 2010 TB/HIV Co-Infection Lisa Y Armitige, MD, PhD June 3, 2010 Tuberculosis and HIV Co-Infection Lisa Y Armitige, MD, PhD Medical Consultant Heartland National TB Center
More informationHIV in in Women Women
HIV in Women Susan L. Koletar, MD The Ohio State University How Many of These Women Have HIV? Answer: I don t really know Google Search: Photos of Groups of Women Pub Med Search: HIV and Women 22,732
More informationTHE SOUTH AFRICAN ANTIRETROVIRAL TREATMENT GUIDELINES 2010
THE SOUTH AFRICAN ANTIRETROVIRAL TREATMENT GUIDELINES 2010 The South African Antiretroviral Treatment Guidelines 2010 Goals of the programme Achieve best health outcomes in the most cost-efficient manner
More informationPregnancy and HIV Reviewing the Vertical Transmission Risks 2015 OCN Education Day V Logan Kennedy RN, MN Research Associate and Clinical Nursing
Pregnancy and HIV Reviewing the Vertical Transmission Risks 2015 OCN Education Day V Logan Kennedy RN, MN Research Associate and Clinical Nursing Specialist Women s College Research Institute, Women s
More informationPAEDIATRIC HIV INFECTION. Dr Ashendri Pillay Paediatric Infectious Diseases Specialist
PAEDIATRIC HIV INFECTION Dr Ashendri Pillay Paediatric Infectious Diseases Specialist Paediatric HIV Infection Epidemiology Immuno-pathogenesis Antiretroviral therapy Transmission Diagnostics Clinical
More information0.14 ( 0.053%) UNAIDS 10% (94) ( ) (73-94/6 ) 8,920
0.14 UNAIDS 0.053% 2 250 60 10% 94 73 20 73-94/6 8,920 12 43 Public Health Service Task Force Recommendations 5-10% for Use of Antiretroviral Drugs in 10-20% Pregnant HIV-1-Infected Women for Maternal
More informationPHCP 403 by L. K. Sarki
PHCP 403 by L. K. Sarki objectives To gain insight into the epidemiology of HIV To gain basic understanding of the etiology of HIV disease To know the clinical manifestations of the disease To gain a basic
More informationWESTERN CAPE ART GUIDELINES PRESENTATION 2013
WESTERN CAPE ART GUIDELINES PRESENTATION 2013 The WC guidelines are based on SA National ART guidelines dated 24th March 2013 Acknowledgement goes to members of the Adult and Paediatric HAST policy advisory
More informationInfertility Treatment and HIV
Infertility Treatment and HIV Infertility Treatment by IVF Or Intra-cytoplasmic Sperm Injections (ICSC) In Chronic HIV-1 Sero- discordant Couples (Poster 670) Retrospective study of outcome of IVF or ICSC
More informationHIV Infection in Pregnancy. Francis J. Ndowa WHO RHR/STI
HIV Infection in Pregnancy Francis J. Ndowa WHO RHR/STI FJN_STI_2005 Department of reproductive health and research Département santé et recherche génésiques Session outline Effect of pregnancy on HIV
More informationHIV Update Objectives. Epidemiology. Epidemiology, Transmission and Natural History. Transmission Risk by Exposure. Transmission 9/29/2014
Objectives HIV Update 2014 Jay Sizemore, MD, MPH Medical Director Chattanooga CARES Assistant Professor UTCOM Chattanooga 2October 2014 Review HIV epidemiology and screening/testing guidelines Discuss
More informationCentral Nervous System Penetration of ARVs: Does it Matter?
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Central Nervous System Penetration of ARVs: Does it Matter? Christina M. Marra, MD Neurology and Medicine (Infectious Diseases) University of Washington 15
More informationPediatric Antiretroviral Resistance Challenges
Pediatric Antiretroviral Resistance Challenges Thanyawee Puthanakit, MD The HIVNAT, Thai Red Cross AIDS research Center The Research Institute for Health Science, Chiang Mai University Outline The burden
More informationInfant feeding in the ARV era. Department of Obstetrics and Gynaecology Faculty of Health Sciences and Tygerberg Hospital
Infant feeding in the ARV era Gerhard Theron Gerhard Theron Department of Obstetrics and Gynaecology Faculty of Health Sciences and Tygerberg Hospital Global HIV infections: 2007 12 countries account for
More informationGaps between Policy and Practice in Managing HIV disease in Asia Pacific
Gaps between Policy and Practice in Managing HIV disease in Asia Pacific Dr. N. Kumarasamy Chief Medical Officer YRGCARE Medical Centre Voluntary Health Services Chief-Chennai Antiviral Research and Treatment
More informationPOST-EXPOSURE PROPHYLAXIS, PRE-EXPOSURE PROPHYLAXIS, & TREATMENT OF HIV
POST-EXPOSURE PROPHYLAXIS, PRE-EXPOSURE PROPHYLAXIS, & TREATMENT OF HIV DISCLOSURE Relevant relationships with commercial entities none Potential for conflicts of interest within this presentation none
More informationHIV Treatment Update. Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University
HIV Treatment Update Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University Outline Rationale for highly active antiretroviral therapy (HAART) When to start
More informationSusan L. Koletar, MD
HIV/AIDS Susan L. Koletar, MD Division Director, Infectious Diseases Professor of Internal Medicine Department of Internal Medicine The Ohio State University Wexner Medical Center HIV through the Decades
More informationBreast Feeding for Women with HIV?
Breast Feeding for Women with HIV? CHIVA / BHIVA Hermione Lyall Imperial Healthcare NHS Trust 17.11.17 Acknowledgements: Nell Freeman-Romilly, Pat Tookey, Claire Townsend, Claire Thorne, Kate Francis,
More informationPage 1. Outline. Outline. Building specialized knowledge: HIV. Biological interactions. Social aspects of the epidemic. Programmatic actions
Harvard-Brazil Collaborative Public Health Field Course January 2014 Lecture # 8 Building specialized knowledge: HIV Aluisio Segurado Department of Infectious Diseases School of Medicine, University of
More informationCriteria for Oral PrEP
Oral PrEP New Drugs Roy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City Safe Criteria for Oral PrEP Penetrates
More informationDr Graham P Taylor Reader in Communicable Diseases
HIV in Pregnancy Joint RCOG/BHIVA Multidisciplinary Conference Dr Graham Taylor Imperial College London Friday 20 January 2012, Royal College of Obstetricians and Gynaecologist, London Prevention of post-partum
More informationPreventing Mother to Child HIV Transmission: Are We There Yet?!'
Preventing Mother to Child HIV Transmission: Are We There Yet?!' 2017 Michigan Clincal Nursing Conference for HIV and STD Care May 18, 2017 Frankenmuth MI 1 Theodore B. Jones, MD Maternal Fetal Medicine
More informationI. HIV Epidemiology. HIV Infection A Primer. Objectives. Disclosures 7/18/2014
Objectives HIV Infection A Primer Discuss the worldwide and domestic epidemiology of HIV infection Review HIV Biology Review HIV Transmission and Prevention Review HIV diagnosis Describe the approaches
More informationIndustry Data Request
Industry Data Request Purpose: reported data will be used internally to populate patient forecasting models that are used for business planning. Business planning includes stock requirement forecasts,
More informationHIV in the Brain MANAGING COMORBIDITIES IN PATIENTS WITH HIV
HIV in the Brain MANAGING COMORBIDITIES IN PATIENTS WITH HIV Shibani S. Mukerji MD, PhD Massachusetts General Hospital, Division of Immunologic, Inflammatory and Infectious Neurological Diseases Dana-Farber
More informationMalaysian Consensus Guidelines on Antiretroviral Therapy Cheng Joo Thye Hospital Raja Permaisuri Bainun Ipoh
Malaysian Consensus Guidelines on Antiretroviral Therapy 2017 Cheng Joo Thye Hospital Raja Permaisuri Bainun Ipoh Acknowledgement Table of contents Evolution of when to initiate therapy ART improves survival
More informationPhase II clinical trial TEmAA. Didier Koumavi EKOUEVI, MD PhD (Principal Investigator)
The combination of Tenofovir-Emtricitabine (Truvada ): a new antiretroviral (ARV) regimen for the prevention of mother-to-child transmission of HIV-1 (PMTCT) in resource-limited settings Phase II clinical
More informationDr Alan Winston. Imperial College Healthcare NHS Trust London. 7-8 October 2010, Queen Elizabeth II Conference Centre, London.
BHIVA AUTUMN CONFERENCE 2010 Including CHIVA Parallel Sessions Dr Alan Winston Imperial College Healthcare NHS Trust London 7-8 October 2010, Queen Elizabeth II Conference Centre, London BHIVA AUTUMN CONFERENCE
More informationHIV associated CNS disease in the era of HAART
HIV associated CNS disease in the era of HAART CSF/CNS penetration and efficacy Acknowledgements Peter Portegies Department of Neurology, AMC Mark van der Valk Department of Internal Medicine/Infectious
More informationPregnancy and HIV. Dr Annemiek de Ruiter. September 2009
Pregnancy and HIV Dr Annemiek de Ruiter September 2009 NSHPC NSHPC update, October 2008 Obstetric and paediatric HIV surveillance data from the UK and Ireland National Study of HIV in Pregnancy and Childhood
More informationStructured Treatment Interruption in HIV Positive Patients. Leah Jackson, BScPhm Pharmacy Resident HIV Rotation January 23, 2007
Structured Treatment Interruption in HIV Positive Patients Leah Jackson, BScPhm Pharmacy Resident HIV Rotation January 23, 2007 Objectives To become re-acquainted with the basics of HAART for HIV infection
More informationPrinciples of Antiretroviral Therapy
Principles of Antiretroviral Therapy Ten Principles of Antiretroviral Therapy Skills Building Workshop: Clinical Management of HIV Infection and Antiretroviral Therapy, 11 th ICAAP, November 21st, 2011,
More informationDr HM Sebitloane Chief Specialist (Outreach) Dept of O+G NRMSM
Dr HM Sebitloane Chief Specialist (Outreach) Dept of O+G NRMSM SA Background Population: 48m Annual number of deliveries:1,2m 97% of women attend the first ANC 71% of women attend 5 th ANC visit 97% of
More informationHIV infection in pregnancy
HIV infection in pregnancy Peter Brocklehurst National Perinatal Epidemiology Unit, University of Oxford What is the size of the problem? in the population as a whole? in women? in pregnant women? in children?
More informationComprehensive Guideline Summary
Comprehensive Guideline Summary Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents AETC NRC Slide Set Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and
More informationSelected Issues in HIV Clinical Trials
Selected Issues in HIV Clinical Trials Judith S. Currier, M.D., MSc Professor of Medicine Division of Infectious Diseases University of California, Los Angeles Issues Evolving Global and Domestic Epidemic
More informationImproving accessibility to antiretroviral drugs: A south-south collaboration
Improving accessibility to antiretroviral drugs: A south-south collaboration Jaideep A Gogtay MD Cipla Ltd Mumbai jgogtay@cipla.com Adults and children estimated to be living with HIV at the end of 2000
More informationContinuing Education for Pharmacy Technicians
Continuing Education for Pharmacy Technicians HIV/AIDS TREATMENT Michael Denaburg, Pharm.D. Birmingham, AL Objectives: 1. Identify drugs and drug classes currently used in the management of HIV infected
More information0% 0% 0% Parasite. 2. RNA-virus. RNA-virus
HIV/AIDS and Treatment Manado, Indonesia 16 november HIV [e] EDUCATION HIV is a 1. DNA-virus 2. RNA-virus 3. Parasite 0% 0% 0% DNA-virus RNA-virus Parasite HIV HIV is a RNA-virus. HIV is an RNA virus which
More informationGuidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents Visit the AIDSinfo website to access the most up-to-date guideline. Register for e-mail notification of guideline
More informationtreatment during pregnancy and breastfeeding
treatment during pregnancy and breastfeeding Topics covered Introduction. Preventing parent-to-child transmission. AZT as a single therapy. Treatment begun late in pregnancy. Nevirapine for mothers and
More informationAll HIV+ Women on Antiretroviral Therapy Should Breastfeed in Both Low and High Resource Settings VOTE NO!!
All HIV+ Women on Antiretroviral Therapy Should Breastfeed in Both Low and High Resource Settings VOTE NO!! Lynne Mofenson MD Elizabeth Glaser Pediatric AIDS Foundation My Esteemed Opponent Will Likely
More informationThe Global HIV Epidemic. Jerome Larkin, MD
The Global HIV Epidemic Jerome Larkin, MD Outline Global Epidemiology Natural History of HIV Antiretroviral Therapy Malaria Tuberculosis Prevention of Mother to Child Transmission Post-Exposure Prophylaxis
More informationSusan L. Koletar, MD
HIV/AIDS Susan L. Koletar, MD Division Director, Infectious Diseases Professor of Internal Medicine Department of Internal Medicine The Ohio State University Wexner Medical Center HIV through the Decades
More information2016 Perinatal Treatment Guidelines Update
Mountain West AIDS Education and Training Center 2016 Perinatal Treatment Guidelines Update Shireesha Dhanireddy, MD Associate Professor of Medicine, University of Washington 2 November 2016 This presentation
More informationScaling up priority HIV/AIDS interventions in the health sector
TOWARDS UNIVERSAL ACCESS? Scaling up priority HIV/AIDS interventions in the health sector Yves Souteyrand, WHO October 2011 Towards universal access targets UN General Assembly High level Meeting June
More informationRegister for notification of guideline updates at
Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States Visit the AIDSinfo website
More informationTORONTO GENERAL HOSPITAL HIV AMBULATORY CARE ROTATION
TGH - ambulatory rotation page 1 of 5 TORONTO GENERAL HOSPITAL HIV AMBULATORY CARE ROTATION SITE: Immunodeficiency Clinic, Toronto General Hospital, University Health Network Location: 13 th floor, Norman
More informationPHARMACOKINETICS OF ANTIRETROVIRAL AND ANTI-HCV AGENTS
8. PHARMACOKINETICS OF ANTIRETROVIRAL AND ANTI-HCV AGENTS David Burger José Moltó Table 8.1a: INFLUENCE OF FOOD ON ABSORPTION (AREA UNDER THE CURVE) OF ANTIRETROVIRAL AGENTS NUCLEOSIDE ANALOGUES NtRTI
More informationWhat s New. In The 2016 Perinatal HIV Treatment Guidelines? Provided by CDC s Elimination of Perinatal HIV Transmission Stakeholders Group
What s New In The 2016 Perinatal HIV Treatment Guidelines? Provided by CDC s Elimination of Perinatal HIV Transmission Stakeholders Group Guidelines for our Online Meeting Room You will be listening to
More informationCUMULATIVE PERINATAL HIV EXPOSURE, AUSTRALIA. Date
CUMULATIVE PERINATAL HIV EXPOSURE, AUSTRALIA 350 300 250 Number 200 150 100 50 0 1/01/1997 1/01/1998 1/01/1999 1/01/2000 31/12/2000 31/12/2001 31/12/2002 Date July 2004 Reported number of perinatally exposed
More informationUsing new ARVs in pregnancy
Using new ARVs in pregnancy Dr Kerry Uebel Slides courtesy of Linda-Gail Bekker With thanks to CN Mnyani SA HIV Clinician s Society Meeting 5 August 2017 We have effective drugs. There is no reason why
More informationPregnancies amongst adolescents and young women 16% of all births - 19% will have repeat pregnancies before age 20
Introduction Pregnancies amongst adolescents and young women 16% of all births - 19% will have repeat pregnancies before age 20 Proportions HIV infections 19% amongst adolescents (- 29.5% nationally 15
More informationUpdate on global guidelines. and emerging issues on perinatal HIV prevention. WHO 2013 Consolidated ARV Guidelines
WHO 2013 Consolidated ARV Guidelines Update on global guidelines H I V / A I D S DEPARTMENT and emerging issues on perinatal HIV prevention Children & HIV, St. Petersburg, Russia Sept 25-26, 2014 Dr. Nathan
More informationPREVENT TRANSMISSION OF HIV/AIDS PREGNANT WOMEN : LITERATUR REVIEW
PREVENT TRANSMISSION OF HIV/AIDS PREGNANT WOMEN : LITERATUR REVIEW *Nunung Nurhayati STIKep PPNI Jawa Barat, Bandung, West Java Indonesia Email: nunky_adzra@yahoo.com ABSTRACT Baby risk be infected HIV/AIDS
More informationActualización y Futuro en VIH
Actualización y Futuro en VIH Dr. Santiago Moreno Servicio de Enfermedades Infecciosas Hospital U. Ramón y Cajal. Universidad de Alcalá. IRYCIS. Madrid Agenda Control of the HIV-epidemic Coinfections Antiretroviral
More informationSecond and third line paediatric ART strategies
Second and third line paediatric ART strategies Dr. Marape Marape Assistant Professor Ohio University School of Health Professions Gaborone, Botswana Marape Marape MB, BCh, BAO, MPH, PhD Assistant Professor
More informationDEPARTMENT. Treatment Recommendations for. Pregnant and Breastfeeding Women: Critical Issues Consolidated ARV Guidelines. Dr.
2013 Consolidated ARV Guidelines H I V / A I D S Treatment Recommendations for DEPARTMENT Pregnant and Breastfeeding Women: Critical Issues Dr. Nathan Shaffer Objectives of Presentation obackground ooverview
More informationObstetrics and HIV An Update. Jennifer Van Horn MD University of Utah
Obstetrics and HIV An Update Jennifer Van Horn MD University of Utah Obstetrics and HIV Perinatal transmission Testing Antiretroviral therapy Antepartum management Intrapartum management Postpartum management
More informationTHE HIV LIFE CYCLE. Understanding How Antiretroviral Medications Work
THE HIV LIFE CYCLE Understanding How Antiretroviral Medications Work DEFINITIONS Host: The animal or cell that another organism lives in. In HIV human CD4 T-cells are the host for HIV. Nucleus: The core
More information2 nd Line Treatment and Resistance. Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012
2 nd Line Treatment and Resistance Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012 Overview Basics of Resistance Treatment failure Strategies to manage treatment failure Mutation Definition: A change
More informationWhat's new in the WHO ART guidelines How did markets react?
WHO 2013 ARV Guidelines What's new in the WHO ART guidelines How did markets react? Dr. J. Perriëns Coordinator, HIV Technology and Commodities HIV department, WHO, Geneva When to start in adults Starting
More informationOutline. Aim with PMTCT. How are children transmitted. Prevention of mother-to-child transmission of HIV. How does HIV transmit to children?
Prevention of mother-to-child transmission of HIV Outline AimofPMTCT How HIV is transmitted to children Epidemiology of HIV in children How to reduce HIV transmission to children Guidelines Lars T. Fadnes
More informationAll HIV-exposed Infants Should Receive Triple Drug Antiretroviral Prophylaxis. Against the motion
All HIV-exposed Infants Should Receive Triple Drug Antiretroviral Prophylaxis Against the motion Hermione Lyall Imperial Healthcare NHS Trust, London, UK Acknowledgements: Pat Tookey, Ali Judd, Claire
More informationPrevention of mother-to-child transmission of HIV. Lars Thore Fadnes Centre for International Health
Prevention of mother-to-child transmission of HIV Lars Thore Fadnes Centre for International Health HIV HIV identified in 1983 AIDS syndrome described in 1981 Kaposi s sarcoma, Pneumocystis jiroveci pnemumonia
More informationVisit Reason: Positive Pregnancy Test. HIV Treatment in the Childbearing Woman
Visit Reason: Positive Pregnancy Test. HIV Treatment in the Childbearing Woman Thi-Thi Nguyen, PharmD, BCPS, AAHIVP Mountain Plains AIDS Education and Training Center Conference August 13th, 2015 1 Objectives
More informationNothing to disclose.
Lisa G. Winston, MD University of California, San Francisco San Francisco General Hospital HIV UPDATE FOR THE PRIMARY CARE PROVIDER Nothing to disclose. 1 Outline Epidemiology Screening / testing for HIV
More informationSomnuek Sungkanuparph, M.D.
HIV Drug Resistance Somnuek Sungkanuparph, M.D. Associate Professor Division of Infectious Diseases Department of Medicine Faculty of Medicine Ramathibodi Hospital Mahidol University Adjunct Professor
More informationUsing new ARVs in pregnancy
Using new ARVs in pregnancy Linda-Gail Bekker With thanks to CN Mnyani SA HIV Clinician s Society Meeting 3 June 2017 We have effective drugs. There is no reason why any mother should die of AIDS. There
More informationManagement of patients with antiretroviral treatment failure: guidelines comparison
The editorial staff Management of patients with antiretroviral treatment failure: guidelines comparison A change of therapy should be considered for patients if they experience sustained rebound in viral
More informationNatural history of HIV Infection
HIV in Primary Care Joint RCGP/BHIVA Multidisciplinary Conference Dr Ian Williams University College London Medical School Friday 25 January 2013, Royal College of General Practitioners, London HIV Treatment
More informationHIV and AIDS. Shan Nanji
HIV and AIDS Shan Nanji HIV 2 Description: Enveloped Positive Sense HIV 3 Structural Genes: Cleavage of gp160 leads to formation of ENV: Gp120: attachment to host CD4 T Cell Gp41: GAG (p24) Capsid protein
More informationSA HIV Clinicians Society Adult ART guidelines
SA HIV Clinicians Society Adult ART guidelines In draft format Graeme Meintjes (on behalf of the guidelines committee) Selected topics When to start ART First-line Second-line Third-line Patients with
More informationHistoric Perspective on HIV and TB Research in Pregnant Women
Historic Perspective on HIV and TB Research in Pregnant Women Lynne M. Mofenson, M.D. Senior HIV Technical Advisor Elizabeth Glaser Pediatric AIDS Foundation High Burden of TB/HIV in Women - 2016 TB HIV
More informationThe NEW ARV Guidelines FAQs
The NEW ARV Guidelines FAQs Dr Madeleine Muller MBChB (Pret).MRCGP(Lon).Dip Hiv Man IYDSA Clinical Advisor Acknowledgments IYDSA for materials and support NDOH for slides CDC our funder HIV Clinician Society
More informationToo small, too soon: antiretroviral prophylaxis and treatment in preterm and low birth weight infants
Too small, too soon: antiretroviral prophylaxis and treatment in preterm and low birth weight infants Mark Mirochnick, MD Boston University School of Medicine, Boston, MA, USA Full Term Full Term 34 wks
More informationTunisian recommendations on ART : process and results
Second Arab Congress of Clinical Microbiology and Infectious Diseases May 24-26, 2012. Tunisian recommendations on ART : process and results M. BEN MAMOU UNAIDS Email: BenmamouM@unaids.org M. CHAKROUN
More informationHIV and the Central Nervous System Impact of Drug Distribution Scott L. Letendre, MD. Professor of Medicine University of California, San Diego
HIV and the Central Nervous System Impact of Drug Distribution Scott L. Letendre, MD Professor of Medicine University of California, San Diego Disclosures Grant/research support Abbvie Gilead Sciences
More informationHIV Drugs and the HIV Lifecycle
HIV Drugs and the HIV Lifecycle Together, we can change the course of the HIV epidemic one woman at a time. #onewomanatatime #thewellproject All HIV drugs work by interrupting different steps in HIV's
More informationWhat to expect. Neonatal HIV management. Background 3/9/2017. ID Update in Children Background. The straightforward.
What to expect Background Neonatal HIV management Prof. Nicolette du Plessis Paediatric Infectious Diseases University of Pretoria nicolette.duplessis@up.ac.za The straightforward The difficult The impossible
More informationSelected Issues in HIV Clinical Trials
Selected Issues in HIV Clinical Trials Judith S. Currier, M.D., MSc Professor of Medicine Division of Infectious Diseases University of California, Los Angeles Issues Evolving Global and Domestic Epidemic
More informationBlood-Borne Pathogens and Post-Exposure Prophylaxis
Blood-Borne Pathogens and Post-Exposure Prophylaxis Christopher Behrens MD Northwest Association of Occupational and Environmental Medicine October 2017 with thanks to Shireesha Dhanireddy MD Disclosures
More informationDistribution and Effectiveness of Antiretrovirals in the Central Nervous System
Distribution and Effectiveness of Antiretrovirals in the Central Nervous System Scott Letendre, MD Associate Professor of Medicine HIV Neurobehavioral Research Center and Antiviral Research Center University
More informationA Descriptive Study of Outcomes of Interventions to Prevent Mother to Child Transmission of HIV in Lusaka, Zambia
ORIGINAL PAPER A Descriptive Study of Outcomes of Interventions to Prevent Mother to Child Transmission of HIV in Lusaka, Zambia Chibesa Shichitamba W, National Malaria Control Centre, Lusaka-Zambia ABSTRACT
More informationScience roadmap on antiretroviral drugs for PMTCT and maternal treatment: current guidance, evidence in development and gaps
Appendix 4 Science roadmap on antiretroviral drugs for PMTCT and maternal treatment: current guidance, evidence in development and gaps Lynne M. Mofenson, MD Eunice Kennedy Shriver National Institute of
More informationAn HIV Update Jan Clark, PharmD Specialty Practice Pharmacist
An HIV Update - 2019 Jan Clark, PharmD Specialty Practice Pharmacist 2 The goal of this program is to provide a review and update of HIV care and to provide a forum for discussing the current local and
More informationModule 2: Integration of HIV Rapid Testing in HIV Prevention and Treatment Programs
Module 2: Integration of HIV Rapid Testing in HIV Prevention and Treatment Programs Purpose Pre-requisite Modules Module Time Learning Objectives To provide the participants with the basic concepts of
More informationTOWARDS ELIMINATION OF MOTHER TO CHILD TRANSMISSION OF HIV
TOWARDS ELIMINATION OF MOTHER TO CHILD TRANSMISSION OF HIV Gladwel Muthoni KPA Conference 24 th April, 2018 OUTLINE Burden of HIV in PMTCT Mechanism and timing of Mother to Child Transmission (MTCT) Four
More informationSecond-Line Therapy NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Second-Line Therapy David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, Division of Infectious Diseases University of Washington Presentation
More information